Jay M. Short was Appointed as Chief Executive Officer at Bioatla

Date of management change: April 15, 2007 

What Happened?

San Diego, CA-based Bioatla has Appointed Jay Short as Chief Executive Officer

 

About the Company

Bioatla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.

 

About the Person

\r\n Jay M. Short is a founder of BioAtla. He also founded Diversa Corp. (now BASF), a developer of enzymes and other biologically active compounds, and served as its CEO, President and CTO from 1994 to 2005. At the time Diversa went public, its $200+ million IPO was the largest one for a biotechnology company up to that time.   Prior to Diversa, Dr. Short served as President of Stratacyte, and VP of R&D and Operations for Stratagene Cloning Systems (now Agilent). Dr. Short received his Ph.D. in Biochemistry from Case Western Reserve University. He is the author of more than 100 publications and is the inventor of over 100 issued patents.   In 2006, Dr. Short was shortlisted by the editors of Nature Biotechnology as a personality making the most significant contribution to biotech in the past decade. He is the recipient of numerous other awards, including Ernst &Young`s Entrepreneur of the Year Award, American Chemical Society`s Henry F. Whalen, Jr. Award for Business Development, Adaptive Business Leaders` Innovations in HealthCare Gold Award, two of Connect`s first place Most Innovative Product Awards, and in 2010 received an international Best-of-the-Best award from the Young Presidents Organization (YPO).    Dr. Short`s board experience includes 15 years as a director of Invitrogen (now Thermo Fisher), Senomyx, Taxon Biosciences, and Ciris Energy. He is a member of YPO/WPO and a founder of Capia IP and the E.O. Wilson Biodiversity Foundation.   Dr. Short serves as an advisor to educational, scientific and charitable organizations.\r\n

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Wylie Devin, McConnell Eric, Piller Jim, O'Brien John, Graham Maria, Brown Monique, Garcia Jose, Boyd Sheena, Cox Julius, Fernandes Sherrie, Henke Rand

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.